Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data - Sattar, N; Preiss, D; Robinson, J; Djedjos, C; Elliott, M; Somaratne, R; Wasserman, S; Raal, F (Lancet Diabetes and Endocrinology, 2016)